AAV ATP7B Gene Therapy for Long-Term Wilson's Disease Correction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Wilson's disease, such as chelating agents and liver transplantation, require lifelong medication and can cause side effects, and do not restore normal copper metabolism, while liver transplantation necessitates immune suppression.
Innovation Solution
A replication-deficient adeno-associated virus (AAV) vector is used to deliver a codon-optimized human copper-transporting ATPase 2 (ATP7B) gene to liver cells, utilizing liver-specific expression control elements for long-term correction of Wilson's disease, reducing circulating copper levels by about 25% or more.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene therapy is administered early in the disease course, then long-term benefits are maximized, but the window for effective intervention is limited and requires early detection
Solution Approach 1:
The patent establishes a preliminary diagnostic framework using genetic testing to identify individuals with Wilson's disease before symptomatic progression occurs. This allows treatment to be initiated in the pre-symptomatic or early symptomatic phase, maximizing therapeutic benefit before irreversible liver damage or neurological decline occurs.
Solution Approach 2:
The patent implements a feedback mechanism through regular monitoring of copper levels, liver function tests, and neurological assessments in treated patients. This allows adjustment of treatment dosage and duration based on disease progression and therapeutic response, ensuring optimal outcomes while minimizing unnecessary treatment exposure.
2Productivity
If aggressive copper chelation therapy is used to rapidly reduce copper levels, then symptom progression is slowed, but side effects from chelating agents increase
Solution Approach 1:
The patent employs parameter changes by adjusting copper removal rates based on disease stage, liver function status, and tolerance to chelating agents. Treatment intensity is modulated over time, starting with lower doses and gradually increasing as patients tolerate therapy, thereby balancing disease control with minimization of adverse effects.
Solution Approach 2:
The patent applies partial action by using copper chelation therapy at sub-maximal intensities for prolonged periods rather than aggressive short-term treatment. This approach gradually reduces copper burden while allowing the body to adapt, reducing the severity of chelation side effects while still achieving disease control.
3Reliability
If liver transplantation is performed to replace damaged liver tissue, then liver function is restored, but it does not address neurological symptoms and requires lifelong immunosuppression
Solution Approach 1:
The patent extracts and treats the underlying metabolic defect through genetic therapy and copper chelation, addressing the root cause of both liver and neurological symptoms. This eliminates the need for liver transplantation by preventing progressive liver failure through early intervention, thereby avoiding lifelong immunosuppression.
Solution Approach 2:
The patent uses copper chelating agents as intermediaries to remove excess copper from both liver and neurological tissues. This single therapeutic approach simultaneously addresses multiple organ systems affected by Wilson's disease, avoiding the need for separate interventions such as liver transplantation and its associated immunosuppression.
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3C
AI summary
Compositions and regimens useful in treating Wilson's Disease are provided. The compositions include recombinant adeno-associated virus (rAAV) with a transthyretin enhancer and promoter driving expression of a human ATP7B.